<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20656" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Donepezil</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kumar</surname>
            <given-names>Anil</given-names>
          </name>
          <aff>Great Plains Health</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gupta</surname>
            <given-names>Vikas</given-names>
          </name>
          <aff>Wellness Psychiatry P.C</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sharma</surname>
            <given-names>Sandeep</given-names>
          </name>
          <aff>Mery Fitzgerald Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anil Kumar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vikas Gupta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sandeep Sharma declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20656.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Donepezil hydrochloride, a piperidine derivative, is a centrally acting, rapid, and reversible acetylcholinesterase inhibitor primarily utilized for treating Alzheimer disease. Acetylcholinesterase is an enzyme that breaks down acetylcholine after its release from the presynapse. By binding reversibly to acetylcholinesterase, donepezil inhibits acetylcholine hydrolysis, thereby increasing acetylcholine availability&#x000a0;at the synapses and enhancing cholinergic transmission. The U.S. Food and Drug Administration (FDA) approved the&#x000a0;drug for the treatment of dementia in mild, moderate, and severe Alzheimer disease. Although there is currently no evidence to suggest that donepezil can alter the progression of the disease, it has shown efficacy in alleviating specific symptoms by improving cognition and/or behavior in affected individuals. In addition to its FDA-approved use in Alzheimer disease, donepezil has various off-label indications. This activity emphasizes the mechanism of action, adverse event profile, pharmacokinetics, monitoring requirements, and relevant drug interactions of donepezil. This information is crucial for interprofessional team members involved in treating patients with dementia associated with Alzheimer disease.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate candidates for donepezil therapy based on clinical criteria and diagnostic guidelines for Alzheimer disease.</p></list-item><list-item><p>Screen patients for potential contraindications, comorbidities, or risk factors associated with donepezil, which may influence the use of the drug in Alzheimer treatment.</p></list-item><list-item><p>Assess the treatment efficacy and tolerability of donepezil in patients with Alzheimer disease through regular cognitive and behavioral evaluations.</p></list-item><list-item><p>Coordinate ongoing monitoring and follow-up care among healthcare professionals, caregivers, and support systems to address the potential issues and complex needs of patients receiving donepezil for Alzheimer disease management.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20656&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20656">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20656.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Donepezil hydrochloride is an acetylcholinesterase inhibitor most commonly used for the treatment of Alzheimer disease.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Donepezil is an FDA-approved medication used for the treatment of dementia in&#x000a0;mild, moderate, and severe Alzheimer disease.<xref ref-type="bibr" rid="article-20656.r1">[1]</xref><xref ref-type="bibr" rid="article-20656.r2">[2]</xref> Although there is currently no evidence to suggest that donepezil can alter the progression of the disease, it can improve cognition and behavior, thereby alleviating certain symptoms. In 2014, the FDA approved a fixed-dose combination of donepezil and memantine for moderate-to-severe dementia associated with Alzheimer disease.<xref ref-type="bibr" rid="article-20656.r3">[3]</xref> More recently, the FDA approved the donepezil transdermal delivery system for the same indications, offering the advantage of easy administration for patients with swallowing difficulties or memory issues who might find it challenging to adhere to a daily oral dose of donepezil.<xref ref-type="bibr" rid="article-20656.r4">[4]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Lewy body dementia:&#x000a0;Several studies have demonstrated the positive effects of donepezil in managing cognitive and behavioral symptoms in individuals with Lewy body dementia.<xref ref-type="bibr" rid="article-20656.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Traumatic brain injury: Emerging research indicates that donepezil therapy may improve memory dysfunction among patients with traumatic brain injury.<xref ref-type="bibr" rid="article-20656.r6">[6]</xref><xref ref-type="bibr" rid="article-20656.r7">[7]</xref><xref ref-type="bibr" rid="article-20656.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>Vascular dementia: Studies have indicated that donepezil may enhance cognition in patients with vascular dementia, although its effect on overall global functioning appears limited.</p>
          </list-item>
          <list-item>
            <p>Dementia-associated with Parkinson disease:&#x000a0;Certain&#x000a0;evidence suggests that donepezil can be beneficial in improving cognition, executive function, and overall global status in individuals with dementia associated with Parkinson disease.<xref ref-type="bibr" rid="article-20656.r8">[8]</xref></p>
          </list-item>
        </list>
        <p>Although researchers have conducted studies on donepezil in patients with schizophrenia, mild cognitive impairment,&#x000a0;attention-deficit hyperactivity disorder (ADHD), multiple sclerosis-related cognitive impairments, post-coronary artery bypass graft (CABG) cognitive impairment, Down syndrome, and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL syndrome), no significant benefits have been conclusively proven yet.<xref ref-type="bibr" rid="article-20656.r9">[9]</xref></p>
        <p>Some small studies have indicated that the use of donepezil could potentially reduce sedation associated with the analgesic use of opioids.<xref ref-type="bibr" rid="article-20656.r10">[10]</xref><xref ref-type="bibr" rid="article-20656.r11">[11]</xref><bold>&#x000a0;</bold>Furthermore, a&#x000a0;recent study suggests that donepezil treatment might be associated with improved outcomes in delirium among individuals with preexisting dementia and critical illness. However, it is essential to conduct extensive research to establish the efficacy and safety of donepezil for all&#x000a0;off-label uses.<xref ref-type="bibr" rid="article-20656.r12">[12]</xref></p>
      </sec>
      <sec id="article-20656.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Donepezil hydrochloride, a piperidine derivative, is a centrally acting, rapid, reversible acetylcholinesterase inhibitor. Acetylcholinesterase is an enzyme that breaks down acetylcholine after its release from the presynapse. Donepezil binds reversibly to acetylcholinesterase, preventing acetylcholine hydrolysis, thereby increasing the availability of acetylcholine at the synapses and enhancing cholinergic transmission. In vitro data suggest that the anticholinesterase activity of donepezil is relatively specific for acetylcholinesterase in the brain. Donepezil is structurally unrelated to other anticholinesterase agents such as tacrine and physostigmine.<xref ref-type="bibr" rid="article-20656.r1">[1]</xref></p>
        <p>In addition to its cholinergic effects, some noncholinergic mechanisms have been proposed for donepezil. Notably, the drug upregulates nicotinic receptors in cortical neurons, which may contribute to its neuroprotective properties. The drug also exhibits reversible inhibition of voltage-activated sodium currents and delays in rectifier potassium currents and fast transient potassium currents. However, these actions are less likely to contribute significantly to its clinical effects.<xref ref-type="bibr" rid="article-20656.r1">[1]</xref><xref ref-type="bibr" rid="article-20656.r11">[11]</xref>&#x000a0;</p>
        <p>Recent findings suggest that neuroinflammation plays a vital role in the pathophysiology of neurodegenerative diseases. Notably, donepezil has been found to have a significant impact on downregulating neuroinflammatory responses, including microglial and astrocytic activation, which are associated with Alzheimer disease.<xref ref-type="bibr" rid="article-20656.r13">[13]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Absorption: Donepezil is efficiently absorbed in the body and exhibits a relative oral bioavailability of 100%. The drug reaches a peak plasma concentration within 3 to 4 hours. Donepezil exhibits linear pharmacokinetics across a dose range of 1 to 10 mg. Notably, the rate and extent of absorption are not influenced&#x000a0;by food consumption or the timing of drug administration. A relative bioavailability study revealed that the exposure to donepezil from once-weekly donepezil transdermal 10 mg per day was equivalent to daily donepezil tablets of 10 mg per day. After administering multiple dosages, reaching a steady state takes approximately 15 days.&#x000a0;The steady-state volume of distribution is 12 L/kg.<xref ref-type="bibr" rid="article-20656.r14">[14]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Distribution: Approximately 96% of donepezil is bound to plasma proteins, primarily albumin (around 75%) and alpha1-acid glycoprotein (21%). Notably, the drug readily crosses the blood-brain barrier.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Metabolism: Donepezil is primarily metabolized in the liver through 3 pathways: CYP2D6, CYP3A4, and glucuronidation. This process produces 4 major metabolites, 2 of which are active, along with several minor metabolites. Notably, donepezil has a prolonged half-life of approximately 70 hours.<xref ref-type="bibr" rid="article-20656.r15">[15]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Excretion: The primary route of excretion for donepezil and its metabolites is through the kidneys, with around 17% of the drug excreted unchanged in the urine. Notably, 2 of these metabolites are known to be active. In addition, approximately 15% to 20% of donepezil is excreted in feces.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20656.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Donepezil hydrochloride is available in multiple formulations, including oral film-coated tablets in 5 mg, 10 mg, and 23 mg strength, all as orally disintegrating tablets in 5 mg and 10 mg strength. In addition, transdermal&#x000a0;donepezil is also available in 5 mg and 10 mg strength.</p>
        <p>
<bold>Dosage</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>For the treatment of mild-to-moderate dementia, the initial recommended dosage of donepezil is 5 mg per day. This dosage can be gradually increased to 10 mg per day for 4 to&#x000a0;6 weeks.</p>
          </list-item>
          <list-item>
            <p>For the treatment of moderate-to-severe dementia, the prescribed dosage of donepezil can be gradually increased to 23 mg daily only after the patient has been taking an initial daily dosage of 10 mg donepezil for&#x000a0;a minimum of 3 months. The 23-mg tablet should be taken as a whole and not crushed, chewed, or split, as doing so may lead to an increased absorption rate. Donepezil is typically administered as a once-daily dose, and its absorption is not affected by food intake or the timing of administration.</p>
          </list-item>
          <list-item>
            <p>The donepezil transdermal system is designed to be applied to the skin once weekly.&#x000a0;Transdermal donepezil is&#x000a0;available as a 5 mg per day patch,&#x000a0;and it can be increased to 10 mg per day if needed. This system provides continuous delivery of donepezil through the skin, ensuring a consistent and steady level of the medication necessary for effective treatment.<xref ref-type="bibr" rid="article-20656.r4">[4]</xref> Patients currently taking 5 mg per day of oral donepezil can be safely switched to the once-weekly 5 mg per day transdermal donepezil. Similarly, patients receiving 10 mg per day of oral donepezil can be transitioned to the once-weekly 10 mg per day transdermal donepezil. In addition, if a patient has already been on 5 mg of oral donepezil for at least 4&#x000a0;to 6 weeks, the physician may consider changing to the once-weekly 10 mg per day transdermal system.</p>
          </list-item>
          <list-item>
            <p>Abrupt discontinuation of donepezil may worsen disease symptoms and severity; gradual tapering is recommended.<xref ref-type="bibr" rid="article-20656.r16">[16]</xref><xref ref-type="bibr" rid="article-20656.r17">[17]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p>Patient with hepatic impairment: Patients with hepatic impairment, including those with compensated liver cirrhosis, do not require any dosage adjustment for donepezil.</p>
        <p>Patient with renal impairment: Patients with moderate-or-severe renal impairment do not require any dosage adjustment for donepezil.<xref ref-type="bibr" rid="article-20656.r18">[18]</xref> However, for patients on hemodialysis, the initial dose of donepezil is reduced to 2.5 mg per day, which may be increased to 5 mg per day based on the patient's clinical condition.<xref ref-type="bibr" rid="article-20656.r19">[19]</xref></p>
        <p>Pregnancy considerations: Donepezil is classified as a pregnancy category C drug. There is insufficient data available regarding the use of donepezil hydrochloride in pregnant women and the potential risk of developmental abnormalities.</p>
        <p>Breastfeeding considerations: The excretion of donepezil or its metabolites in breast milk is currently unknown.</p>
        <p>Pediatric patients: The safety and efficacy of donepezil treatment in children remain uncertain, and no pediatric indications are approved for its use.</p>
        <p>Older patients: Due to an increased steady-state volume of distribution throughout the whole body, the elimination half-life of donepezil is prolonged in older patients (approximately 100 hours). However, no dosage adjustment is required for older patients as steady-state clearance remains similar across all age groups.<xref ref-type="bibr" rid="article-20656.r14">[14]</xref></p>
      </sec>
      <sec id="article-20656.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most common adverse effects of donepezil are gastrointestinal (GI), which may include nausea, diarrhea, and vomiting. In addition, other common adverse effects such as insomnia, muscle cramps, fatigue, and anorexia are more frequently reported with higher doses of donepezil. However, these adverse effects are typically mild and transient in most patients, lasting for up to 3 weeks, and they usually resolve even with continued use of the medication.<xref ref-type="bibr" rid="article-20656.r11">[11]</xref><xref ref-type="bibr" rid="article-20656.r20">[20]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Due to its vagotonic properties, donepezil can lead to bradycardia and heart block, even in patients with or without known underlying cardiac conduction abnormalities. Additionally, there have been reports of syncopal episodes associated with donepezil.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Other infrequent adverse effects of donepezil on the cardiovascular system include hypertension, edema, electrocardiogram (EKG) abnormalities, and hypotension.</p>
          </list-item>
          <list-item>
            <p>Donepezil can cause weight loss in approximately 5% of patients, with a higher incidence observed at higher doses.</p>
          </list-item>
          <list-item>
            <p>Similar to other cholinesterase inhibitors, donepezil can induce nightmares due to enhanced activation of the visual association cortex during rapid eye movement (REM) sleep. However, administering donepezil in the morning may help reduce the frequency of nightmares.</p>
          </list-item>
          <list-item>
            <p>In some rare instances, the usage of donepezil has been linked to cases of neuroleptic malignant syndrome.</p>
          </list-item>
          <list-item>
            <p>Although rare, rhabdomyolysis has been reported as an adverse event with donepezil.</p>
          </list-item>
          <list-item>
            <p>Drug-induced liver injury (DILI) associated with donepezil typically occurs within 1 to 6 weeks after initiation of treatment. The pattern of serum enzyme elevations is often cholestatic or mixed. Hepatotoxicity is likely due to idiosyncratic mechanisms involving toxic immunogenic metabolites. The course of hepatotoxicity can be severe, leading to prolonged jaundice, but reported case fatalities are&#x000a0;uncommon.<xref ref-type="bibr" rid="article-20656.r21">[21]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Donepezil exhibits synergistic effects when combined with other cholinesterase-blocking agents such as neostigmine and physostigmine.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Donepezil can potentially prolong the effects of depolarizing neuromuscular blocking agents such as suxamethonium.<xref ref-type="bibr" rid="article-20656.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p>Donepezil may elevate the risk of bradycardia when used concurrently with beta-blockers such as carvedilol, metoprolol, atenolol, and propranolol.<xref ref-type="bibr" rid="article-20656.r23">[23]</xref></p>
          </list-item>
          <list-item>
            <p>CYP2D6 and CYP3A4 inducers, such as phenytoin, carbamazepine, phenobarbital, rifampin, and dexamethasone, have the potential to reduce donepezil levels by increasing their elimination rate.<xref ref-type="bibr" rid="article-20656.r24">[24]</xref></p>
          </list-item>
          <list-item>
            <p>Theoretically, inhibitors of CYP3A4 and CYP2D6, such as ketoconazole and quinidine, can potentially inhibit the metabolism of donepezil. However, the clinical significance of this interaction is currently unknown and requires further investigation.<xref ref-type="bibr" rid="article-20656.r25">[25]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20656.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Donepezil is contraindicated for patients with a known hypersensitivity to donepezil hydrochloride or piperidine derivatives.</p>
        <p>
<bold>Box Warning</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Donepezil can potentially cause QT interval prolongation; therefore, its use should be exercised with caution in patients at risk of prolonged cardiac repolarization. Furthermore, caution is advised in patients with symptomatic bradycardia, sick sinus syndrome, or cardiac conduction abnormalities, as donepezil can induce bradycardia and/or heart blocks.<xref ref-type="bibr" rid="article-20656.r23">[23]</xref></p>
          </list-item>
          <list-item>
            <p>Donepezil and other cholinomimetic agents have the potential to trigger seizures. Therefore, clinicians should be cautious when prescribing it to patients with a history of seizure disorder.</p>
          </list-item>
          <list-item>
            <p>Cholinomimetic agents, including donepezil, have the potential to cause or exacerbate bladder outflow obstruction. Therefore, caution is necessary when prescribing these medications to patients with a history of prostatic hyperplasia.</p>
          </list-item>
          <list-item>
            <p>Cholinesterase inhibitors, including donepezil, can lead to increased gastric acid secretion. Hence, caution should be exercised when prescribing these medications to patients at risk of ulcer disease. In addition, monitoring for symptoms of&#x000a0;GI bleeding is essential.<xref ref-type="bibr" rid="article-20656.r26">[26]</xref></p>
          </list-item>
          <list-item>
            <p>Donepezil can potentiate muscle relaxation induced by succinylcholine during anesthesia.<xref ref-type="bibr" rid="article-20656.r27">[27]</xref></p>
          </list-item>
          <list-item>
            <p>Donepezil should be prescribed cautiously to patients with a history of asthma or obstructive pulmonary disease because of its cholinomimetic properties.<xref ref-type="bibr" rid="article-20656.r28">[28]</xref></p>
          </list-item>
          <list-item>
            <p>Donepezil should be used with caution in patients at risk for rhabdomyolysis. Risk factors include a history of muscular disorders, uncontrolled hypothyroidism, and concomitant use of medications associated with rhabdomyolysis.<xref ref-type="bibr" rid="article-20656.r29">[29]</xref></p>
          </list-item>
          <list-item>
            <p>Transdermal donepezil is contraindicated in patients with a prior history of allergic contact dermatitis to the donepezil transdermal system.<xref ref-type="bibr" rid="article-20656.r4">[4]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20656.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Some data suggest that therapeutic drug monitoring may enhance&#x000a0;the effectiveness of donepezil treatment. However, routine monitoring of donepezil drug levels is not generally recommended or indicated.<xref ref-type="bibr" rid="article-20656.r30">[30]</xref>&#x000a0;A comprehensive baseline dementia assessment should be conducted before initiating donepezil therapy. Subsequently, all follow-up appointments should include regular evaluations of cognition and behavior to assess the effectiveness of treatment. Screening scales such as the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) and the Montreal Cognitive Assessment (MoCA) can be utilized to identify and monitor mild cognitive impairment (MCI) and Alzheimer disease.<xref ref-type="bibr" rid="article-20656.r31">[31]</xref><xref ref-type="bibr" rid="article-20656.r32">[32]</xref>&#x000a0;</p>
        <p>According to the American Academy of Neurology,&#x000a0;it is essential to screen patients and appropriately manage their conditions,&#x000a0;including MCI, depression, sleep apnea, adverse effects of medications (eg, anticholinergics and benzodiazepines), and other medical illnesses.<xref ref-type="bibr" rid="article-20656.r33">[33]</xref></p>
      </sec>
      <sec id="article-20656.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>General supportive measures are crucial for a donepezil overdose, and the clinician should immediately contact the poison control center. An overdose of donepezil can trigger a cholinergic crisis, leading to severe symptoms like nausea, vomiting, excessive sweating, and salivation. Furthermore, bradycardia, hypotension, respiratory depression, collapse, and seizures are potential manifestations of an overdose.<xref ref-type="bibr" rid="article-20656.r34">[34]</xref></p>
        <p>An overdose of donepezil can lead to increased muscle weakness and may even result in death in severe cases involving respiratory muscles. Some reported cases of overdose have also shown hepatotoxicity. As with other anticholinesterase inhibitor toxicities, tertiary anticholinergics, such as atropine, may be used as an antidote for donepezil overdose. The intravenous atropine dose should be titrated based on the patient's clinical response. Currently, the information on whether donepezil or its metabolites can be removed through hemodialysis, peritoneal dialysis, or hemofiltration is unknown.<xref ref-type="bibr" rid="article-20656.r35">[35]</xref><xref ref-type="bibr" rid="article-20656.r36">[36]</xref>&#x000a0;</p>
        <p>Clinicians should be aware that the clinical presentation of donepezil toxicity can resemble a beta-blocker overdose. Therefore, it is crucial to reassess the diagnosis if the patient does not respond as expected to standard therapy.<xref ref-type="bibr" rid="article-20656.r37">[37]</xref></p>
      </sec>
      <sec id="article-20656.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Donepezil is&#x000a0;primarily used for the treatment of dementia associated with Alzheimer disease and has FDA approval for use in mild, moderate, and severe stages of the disease. Educating the family and caregivers about the fact that donepezil does not alter the progression of Alzheimer disease is vital to establish realistic expectations for this treatment. However,&#x000a0;donepezil can temporarily alleviate some&#x000a0;symptoms by improving cognition and behavior.</p>
        <p>Healthcare professionals, including clinicians, must be aware of the benefits and limitations of donepezil when prescribing&#x000a0;the drug to older adults. After initiating treatment, physicians should conduct regular follow-ups for cognition and behavior assessments to evaluate the effectiveness of the medication and check for drug tolerance. In addition, monitoring for any symptoms of cholinergic excess is essential during treatment. A pharmacist consultation should include verifying the dosing, reconciling medication, and checking for potential drug-drug interactions. If any issues arise, the pharmacist should promptly report them to the prescriber. On the other hand, nurses should diligently monitor for adverse effects, assess medication compliance, and evaluate the therapeutic effectiveness of the treatment. Interprofessional team members need to collaborate and&#x000a0;work together and set clear patient, family, and caregiver expectations regarding the expected outcomes of donepezil and other pharmaceutical therapies used to treat Alzheimer disease.</p>
        <p>Consulting with neurologists is&#x000a0;of utmost importance&#x000a0;for the&#x000a0;treatment of severe Alzheimer disease. The management of dementia necessitates an interprofessional team approach involving healthcare professionals such as physicians, advanced practice practitioners, specialists, nursing staff, and pharmacists, as well as the involvement of family and caregivers. Collaborative decision-making and open communication among all team members are essential in driving optimal patient outcomes.<xref ref-type="bibr" rid="article-20656.r1">[1]</xref><xref ref-type="bibr" rid="article-20656.r2">[2]</xref> Research highlights the significance of an interprofessional team approach, particularly the collaboration between advanced practice practitioners and physicians, working with the patient's family caregiver to achieve optimal outcomes in primary care settings.<xref ref-type="bibr" rid="article-20656.r38">[38]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-20656.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20656&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20656">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20656/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20656">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-20656.s11">
        <title>References</title>
        <ref id="article-20656.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seltzer</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Donepezil: a review.</article-title>
            <source>Expert Opin Drug Metab Toxicol</source>
            <year>2005</year>
            <month>Oct</month>
            <volume>1</volume>
            <issue>3</issue>
            <fpage>527</fpage>
            <page-range>527-36</page-range>
            <pub-id pub-id-type="pmid">16863459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Kumar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sidhu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lui</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tsao</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <chapter-title>Alzheimer Disease</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>2</month>
            <day>12</day>
            <pub-id pub-id-type="pmid">29763097</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morant</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Vestergaard</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Lassen</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Navikas</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>US, EU, and Japanese Regulatory Guidelines for Development of Drugs for Treatment of Alzheimer's Disease: Implications for Global Drug Development.</article-title>
            <source>Clin Transl Sci</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>652</fpage>
            <page-range>652-664</page-range>
            <pub-id pub-id-type="pmid">32043310</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Larkin</surname>
                <given-names>HD</given-names>
              </name>
            </person-group>
            <article-title>First Donepezil Transdermal Patch Approved for Alzheimer Disease.</article-title>
            <source>JAMA</source>
            <year>2022</year>
            <month>May</month>
            <day>03</day>
            <volume>327</volume>
            <issue>17</issue>
            <fpage>1642</fpage>
            <pub-id pub-id-type="pmid">35503362</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Szigeti</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hafeez</surname>
                <given-names>MU</given-names>
              </name>
            </person-group>
            <article-title>Exploring the role of donepezil in dementia with Lewy bodies.</article-title>
            <source>Drugs Today (Barc)</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>51</volume>
            <issue>10</issue>
            <fpage>579</fpage>
            <page-range>579-90</page-range>
            <pub-id pub-id-type="pmid">26583300</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morey</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Cilo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Berry</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cusick</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The effect of Aricept in persons with persistent memory disorder following traumatic brain injury: a pilot study.</article-title>
            <source>Brain Inj</source>
            <year>2003</year>
            <month>Sep</month>
            <volume>17</volume>
            <issue>9</issue>
            <fpage>809</fpage>
            <page-range>809-15</page-range>
            <pub-id pub-id-type="pmid">12850946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ballesteros</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>G&#x000fc;emes</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ibarra</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Quemada</surname>
                <given-names>JI</given-names>
              </name>
            </person-group>
            <article-title>The effectiveness of donepezil for cognitive rehabilitation after traumatic brain injury: a systematic review.</article-title>
            <source>J Head Trauma Rehabil</source>
            <year>2008</year>
            <season>May-Jun</season>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>171</fpage>
            <page-range>171-80</page-range>
            <pub-id pub-id-type="pmid">18520431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dubois</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tolosa</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Katzenschlager</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Emre</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lees</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Schumann</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pourcher</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Swartz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Moline</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study.</article-title>
            <source>Mov Disord</source>
            <year>2012</year>
            <month>Sep</month>
            <day>01</day>
            <volume>27</volume>
            <issue>10</issue>
            <fpage>1230</fpage>
            <page-range>1230-8</page-range>
            <pub-id pub-id-type="pmid">22915447</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kishnani</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Sommer</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Handen</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Seltzer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Capone</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Spiridigliozzi</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Heller</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McRae</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome.</article-title>
            <source>Am J Med Genet A</source>
            <year>2009</year>
            <month>Aug</month>
            <volume>149A</volume>
            <issue>8</issue>
            <fpage>1641</fpage>
            <page-range>1641-54</page-range>
            <pub-id pub-id-type="pmid">19606472</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Carroll</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Woodruff</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Locke</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Hoffman-Snyder</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Wellik</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Thaera</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Demaerschalk</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Wingerchuk</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Is donepezil effective for multiple sclerosis-related cognitive dysfunction? A critically appraised topic.</article-title>
            <source>Neurologist</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>51</fpage>
            <page-range>51-4</page-range>
            <pub-id pub-id-type="pmid">22217618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seltzer</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Donepezil: an update.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2007</year>
            <month>May</month>
            <volume>8</volume>
            <issue>7</issue>
            <fpage>1011</fpage>
            <page-range>1011-23</page-range>
            <pub-id pub-id-type="pmid">17472546</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lieberman</surname>
                <given-names>OJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zabinski</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Donepezil treatment is associated with improved outcomes in critically ill dementia patients via a reduction in delirium.</article-title>
            <source>Alzheimers Dement</source>
            <year>2023</year>
            <month>May</month>
            <volume>19</volume>
            <issue>5</issue>
            <fpage>1742</fpage>
            <page-range>1742-1751</page-range>
            <pub-id pub-id-type="pmid">36218161</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Jeong</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Seol</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hoe</surname>
                <given-names>HS</given-names>
              </name>
            </person-group>
            <article-title>Donepezil Regulates LPS and A&#x003b2;-Stimulated Neuroinflammation through MAPK/NLRP3 Inflammasome/STAT3 Signaling.</article-title>
            <source>Int J Mol Sci</source>
            <year>2021</year>
            <month>Sep</month>
            <day>30</day>
            <volume>22</volume>
            <issue>19</issue>
            <pub-id pub-id-type="pmid">34638977</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shigeta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Homma</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Donepezil for Alzheimer's disease: pharmacodynamic, pharmacokinetic, and clinical profiles.</article-title>
            <source>CNS Drug Rev</source>
            <year>2001</year>
            <season>Winter</season>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>353</fpage>
            <page-range>353-68</page-range>
            <pub-id pub-id-type="pmid">11830754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cacabelos</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics.</article-title>
            <source>Neuropsychiatr Dis Treat</source>
            <year>2007</year>
            <month>Jun</month>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>303</fpage>
            <page-range>303-33</page-range>
            <pub-id pub-id-type="pmid">19300564</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Howard</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McShane</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lindesay</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ritchie</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Baldwin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barber</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Burns</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dening</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Findlay</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jacoby</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McKeith</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Macharouthu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Passmore</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sheehan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Juszczak</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Katona</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hills</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Knapp</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ballard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Banerjee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Onions</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bentham</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Donepezil and memantine for moderate-to-severe Alzheimer's disease.</article-title>
            <source>N Engl J Med</source>
            <year>2012</year>
            <month>Mar</month>
            <day>08</day>
            <volume>366</volume>
            <issue>10</issue>
            <fpage>893</fpage>
            <page-range>893-903</page-range>
            <pub-id pub-id-type="pmid">22397651</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reeve</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Farrell</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Herrmann</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sketris</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Magin</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Chenoweth</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gorman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Quirke</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bethune</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hilmer</surname>
                <given-names>SN</given-names>
              </name>
            </person-group>
            <article-title>Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary.</article-title>
            <source>Med J Aust</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>210</volume>
            <issue>4</issue>
            <fpage>174</fpage>
            <page-range>174-179</page-range>
            <pub-id pub-id-type="pmid">30771226</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nagy</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cullen</surname>
                <given-names>EI</given-names>
              </name>
              <name>
                <surname>Bolton</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Marbury</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Gutierrez</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Hutman</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Pratt</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2004</year>
            <month>Nov</month>
            <volume>58 Suppl 1</volume>
            <issue>Suppl 1</issue>
            <fpage>18</fpage>
            <page-range>18-24</page-range>
            <pub-id pub-id-type="pmid">15496219</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yiannopoulou</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Anastasiou</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Kyrozis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Anastasiou</surname>
                <given-names>IP</given-names>
              </name>
            </person-group>
            <article-title>Donepezil Treatment for Alzheimer's Disease in Chronic Dialysis Patients.</article-title>
            <source>Case Rep Nephrol Dial</source>
            <year>2019</year>
            <season>Sep-Dec</season>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>126</fpage>
            <page-range>126-136</page-range>
            <pub-id pub-id-type="pmid">31616673</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bryson</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Benfield</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Donepezil.</article-title>
            <source>Drugs Aging</source>
            <year>1997</year>
            <month>Mar</month>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>234</fpage>
            <page-range>234-9; discussion 240-1</page-range>
            <pub-id pub-id-type="pmid">9108896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r21">
          <label>21</label>
          <element-citation publication-type="book">
            <chapter-title>Donepezil</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>1</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">31643523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heath</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Donepezil, Alzheimer's disease and suxamethonium.</article-title>
            <source>Anaesthesia</source>
            <year>1997</year>
            <month>Oct</month>
            <volume>52</volume>
            <issue>10</issue>
            <fpage>1018</fpage>
            <pub-id pub-id-type="pmid">9370854</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kho</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ioannou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mandal</surname>
                <given-names>AKJ</given-names>
              </name>
              <name>
                <surname>Cox</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nasim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Metaxa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Missouris</surname>
                <given-names>CG</given-names>
              </name>
            </person-group>
            <article-title>Long term use of donepezil and QTc prolongation.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>59</volume>
            <issue>3</issue>
            <fpage>208</fpage>
            <page-range>208-214</page-range>
            <pub-id pub-id-type="pmid">32609550</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levy</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Risk and predictability of drug interactions in the elderly.</article-title>
            <source>Int Rev Neurobiol</source>
            <year>2007</year>
            <volume>81</volume>
            <fpage>235</fpage>
            <page-range>235-51</page-range>
            <pub-id pub-id-type="pmid">17433928</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pasqualetti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tognini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Calsolaro</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Polini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Monzani</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Potential drug-drug interactions in Alzheimer patients with behavioral symptoms.</article-title>
            <source>Clin Interv Aging</source>
            <year>2015</year>
            <volume>10</volume>
            <fpage>1457</fpage>
            <page-range>1457-66</page-range>
            <pub-id pub-id-type="pmid">26392756</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kok</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Loke</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Southgate</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Upper gastrointestinal bleed associated with cholinesterase inhibitor use.</article-title>
            <source>BMJ Case Rep</source>
            <year>2015</year>
            <month>Sep</month>
            <day>29</day>
            <volume>2015</volume>
            <pub-id pub-id-type="pmid">26420698</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heath</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Donepezil and succinylcholine.</article-title>
            <source>Anaesthesia</source>
            <year>2003</year>
            <month>Feb</month>
            <volume>58</volume>
            <issue>2</issue>
            <fpage>202</fpage>
            <pub-id pub-id-type="pmid">12562439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lampela</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tolppanen</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Koponen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tanskanen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tiihonen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hartikainen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Taipale</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Asthma and Chronic Obstructive Pulmonary Disease as a Comorbidity and Association with the Choice of Antidementia Medication Among Persons with Alzheimer's Disease.</article-title>
            <source>J Alzheimers Dis</source>
            <year>2020</year>
            <volume>73</volume>
            <issue>3</issue>
            <fpage>1243</fpage>
            <page-range>1243-1251</page-range>
            <pub-id pub-id-type="pmid">31929157</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fleet</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>McArthur</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weir</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Montero-Odasso</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Garg</surname>
                <given-names>AX</given-names>
              </name>
            </person-group>
            <article-title>Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study.</article-title>
            <source>CMAJ</source>
            <year>2019</year>
            <month>Sep</month>
            <day>16</day>
            <volume>191</volume>
            <issue>37</issue>
            <fpage>E1018</fpage>
            <page-range>E1018-E1024</page-range>
            <pub-id pub-id-type="pmid">31527187</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hefner</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Brueckner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hiemke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fellgiebel</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic drug monitoring for patients with Alzheimer dementia to improve treatment with donepezil.</article-title>
            <source>Ther Drug Monit</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>353</fpage>
            <page-range>353-61</page-range>
            <pub-id pub-id-type="pmid">25384119</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Freitas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sim&#x000f5;es</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Alves</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Santana</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Montreal cognitive assessment: validation study for mild cognitive impairment and Alzheimer disease.</article-title>
            <source>Alzheimer Dis Assoc Disord</source>
            <year>2013</year>
            <season>Jan-Mar</season>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>37</fpage>
            <page-range>37-43</page-range>
            <pub-id pub-id-type="pmid">22193353</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kueper</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Speechley</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Montero-Odasso</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): Modifications and Responsiveness in&#x000a0;Pre-Dementia Populations. A Narrative Review.</article-title>
            <source>J Alzheimers Dis</source>
            <year>2018</year>
            <volume>63</volume>
            <issue>2</issue>
            <fpage>423</fpage>
            <page-range>423-444</page-range>
            <pub-id pub-id-type="pmid">29660938</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Petersen</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Lopez</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Getchius</surname>
                <given-names>TSD</given-names>
              </name>
              <name>
                <surname>Ganguli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gloss</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gronseth</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Marson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pringsheim</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Sager</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rae-Grant</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.</article-title>
            <source>Neurology</source>
            <year>2018</year>
            <month>Jan</month>
            <day>16</day>
            <volume>90</volume>
            <issue>3</issue>
            <fpage>126</fpage>
            <page-range>126-135</page-range>
            <pub-id pub-id-type="pmid">29282327</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greene</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Noviasky</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tariot</surname>
                <given-names>PN</given-names>
              </name>
            </person-group>
            <article-title>Donepezil overdose.</article-title>
            <source>J Clin Psychiatry</source>
            <year>1999</year>
            <month>Jan</month>
            <volume>60</volume>
            <issue>1</issue>
            <fpage>56</fpage>
            <page-range>56-7</page-range>
            <pub-id pub-id-type="pmid">10074883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pourmand</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shay</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Redha</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Aalam</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mazer-Amirshahi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cholinergic symptoms and QTc prolongation following donepezil overdose.</article-title>
            <source>Am J Emerg Med</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>35</volume>
            <issue>9</issue>
            <fpage>1386.e1</fpage>
            <page-range>1386.e1-1386.e3</page-range>
            <pub-id pub-id-type="pmid">28668178</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shepherd</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Klein-Schwartz</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Donepezil overdose: a tenfold dosing error.</article-title>
            <source>Ann Pharmacother</source>
            <year>1999</year>
            <season>Jul-Aug</season>
            <volume>33</volume>
            <issue>7-8</issue>
            <fpage>812</fpage>
            <page-range>812-5</page-range>
            <pub-id pub-id-type="pmid">10466911</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gust</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pugliese</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Stern</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Suspected donepezil toxicity: A case report.</article-title>
            <source>Clin Case Rep</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>8</volume>
            <issue>12</issue>
            <fpage>2818</fpage>
            <page-range>2818-2823</page-range>
            <pub-id pub-id-type="pmid">33363829</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20656.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Callahan</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Boustani</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Unverzagt</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>Austrom</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Damush</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Perkins</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Fultz</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Hui</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Counsell</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Hendrie</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness of collaborative care for older adults with Alzheimer disease in primary care: a randomized controlled trial.</article-title>
            <source>JAMA</source>
            <year>2006</year>
            <month>May</month>
            <day>10</day>
            <volume>295</volume>
            <issue>18</issue>
            <fpage>2148</fpage>
            <page-range>2148-57</page-range>
            <pub-id pub-id-type="pmid">16684985</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
